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Abstract
Background: Recent studies indicate that the G protein-coupled receptor (GPCR) signaling machinery
can serve as a direct target of reactive oxygen species, including nitric oxide (NO) and S-nitrosothiols
(RSNOs). To gain a broader view into the way that receptor-dependent G protein activation – an early
step in signal transduction – might be affected by RSNOs, we have studied several receptors coupling to
the Gi family of G proteins in their native cellular environment using the powerful functional approach of
[35S]GTPγ S autoradiography with brain cryostat sections in combination with classical G protein activation
assays.
Results:  We demonstrate that RSNOs, like S-nitrosoglutathione (GSNO) and S-nitrosocysteine
(CysNO), can modulate GPCR signaling via reversible, thiol-sensitive mechanisms probably involving S-
nitrosylation. RSNOs are capable of very targeted regulation, as they potentiate the signaling of some
receptors (exemplified by the M2/M4 muscarinic cholinergic receptors), inhibit others (P2Y12 purinergic,
LPA1lysophosphatidic acid, and cannabinoid CB1 receptors), but may only marginally affect signaling of
others, such as adenosine A1, µ-opioid, and opiate related receptors. Amplification of M2/M4 muscarinic
responses is explained by an accelerated rate of guanine nucleotide exchange, as well as an increased
number of high-affinity [35S]GTPγ S binding sites available for the agonist-activated receptor. GSNO
amplified human M4 receptor signaling also under heterologous expression in CHO cells, but the effect
diminished with increasing constitutive receptor activity. RSNOs markedly inhibited P2Y12 receptor
signaling in native tissues (rat brain and human platelets), but failed to affect human P2Y12 receptor signaling
under heterologous expression in CHO cells, indicating that the native cellular signaling partners, rather
than the P2Y12 receptor protein, act as a molecular target for this action.
Conclusion: These in vitro studies show for the first time in a broader general context that RSNOs are
capable of modulating GPCR signaling in a reversible and highly receptor-specific manner. Given that the
enzymatic machinery responsible for endogenous NO production is located in close proximity with the
GPCR signaling complex, especially with that for several receptors whose signaling is shown here to be
modulated by exogenous RSNOs, our data suggest that GPCR signaling in vivo is likely to be subject to
substantial, and highly receptor-specific modulation by NO-derived RSNOs.
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Background
G protein-coupled receptors (GPCRs) represent the largest
group of integral membrane proteins involved in signal
transduction and are the most important targets of clini-
cally marketed drugs [1-3]. The known GPCRs mediate
messages from ligands as diverse as neurotransmitters,
lipid mediators, hormones, and sensory stimuli [4]. The
classical scheme of GPCR signaling implies that agonist-
induced conformational changes in receptor molecule
will result in activation of cognate G proteins and subse-
quently in the regulation of downstream effectors, second
messengers, and the activation of protein kinases, for
example [4]. However, recent work has indicated that
GPCR signaling is subject to complex, cell-type specific
regulation, involving a plethora of kinases, as well as
newly-identified signaling partners, such as regulators of
G protein signaling (RGS) [5], and activators of G protein
signaling (AGS) [6].
Nitric oxide (NO) is a unique gaseous messenger gener-
ated in vivo by three isoforms of NO synthases (NOS).
The established mode of NO signaling is through the acti-
vation of the hemoprotein, soluble guanylyl cyclase,
resulting in increased production of the second messenger
cGMP. However, accumulating evidence points towards
cGMP-independent mechanisms by which NO can react
with proteins, forming covalent post-translational modi-
fications [7]. S-nitrosothiols (RSNOs) are biological
metabolites of NO, that may prolong and spatially extend
the in vivo actions of locally produced NO [8]. NO and
RSNOs can reversibly react with free SH-groups of target
cysteine (Cys) residues, including those in proteins, lead-
ing to S-nitrosylation and/or S-thiolation (disulfide link-
age of low-molecular weight thiols to proteins) [8-17]. A
broad functional spectrum of potential S-nitrosylation
target proteins is currently recognized. A growing list of
targets include ion channels, transporters, transcription
factors, signaling proteins, metabolic enzymes, as well as
respiratory proteins [7,14,18-20]. Although individual
components of the GPCR signaling machinery are impli-
cated as potential targets of reactive oxygen species (ROS),
including NO [21-35], a broader view on how NO, and
RSNOs in particular, might modulate GPCR signaling, has
not been established.
To begin to address these issues, we have studied how
exogenous RSNOs affect receptor-mediated G protein
activity – a very proximal step of GPCR signal transduc-
tion – by studying the signaling of several receptors that
couple to the Gi family of heterotrimeric G proteins. This
family consists of both pertussis toxin sensitive (Gα i1-3,
Gα o, transducin, gustducin) and insensitive (Gα z) mem-
bers. We applied the powerful functional approach of
[35S]GTPγ S autoradiography in brain cryostat sections, as
this technique allows selective detection of receptor-
dependent G protein activity simultaneously in multiple
brain regions with minimal disturbance of the GPCR
microenvironment [36]. We anticipated that accessibility
of target thiols would be minimally disturbed in cryostat
sections. Moreover, it is increasingly recognized that spe-
cialized plasma membrane microdomains (variously
described as detergent-resistant fractions, low-density
fractions, lipid rafts, or caveolae) act as unique signaling
platforms with specific enrichment of GPCRs, their cog-
nate G proteins, as well as effectors [37-40]. Such an
enrichment is thought to be well-preserved in cryostat sec-
tions, but might be compromised to a variable extent [38],
or even lost in bulk membrane preparations obtained
using traditional protocols. To complement the autoradi-
ography approach, we used membrane and lysate
[35S]GTPγ S binding assays to more systematically study
the effects of RSNOs on a panel of Gi-coupled receptors in
native tissues. Signaling of selected receptors was further
studied after their heterologous expression in Chinese
hamster ovary (CHO) cells. Our studies reveal highly
receptor-specific modulation of GPCR signaling by
RSNOs, as signaling of some receptors can be amplified,
or inhibited, whereas for others, the activity is only mar-
ginally affected by comparable treatments. The GPCR
itself and/or its native signaling partners seem to act as
potential targets of RSNO action, and therefore their mod-
ulation may be diminished, or even totally masked under
heterologous expression.
Results
Exogenous RSNOs modulate GPCR signaling via 
mechanisms likely involving S-nitrosylation
We used the functional approach of [35S]GTPγ S autoradi-
ography, as this technique allows selective detection of
receptor-stimulated Gi protein activity simultaneously in
multiple brain structures with minimal disturbance of the
GPCR microenvironment [36]. We focused the initial
experiments on three Gi-linked receptors, namely M2/M4
AChRs, the P2Y12 purinoceptor, and the LPA1 receptor, as
G protein activity upon stimulation of these receptors has
been previously characterized using the autoradiography
approach and each receptor shows a unique anatomical
distribution pattern in the developing rat brain [36,41-
43]. As depicted in Figure 1, pretreatment of brain sec-
tions with freshly prepared GSNO (0.5 mM) had distinct
effects on basal and receptor-stimulated [35S]GTPγ S bind-
ing responses. In GSNO-treated sections, basal G protein
activity was increased throughout the gray matter areas
and this effect was fully reversed in the presence of excess
thiol, either in the form of dithiotreitol (DTT) or reduced
glutathione (GSH). The autoradiography images were
quantified for selected brain regions and these results are
shown in Supplementary Figures 1 and 2 [see additional
file 1]. Consistent with the anatomical distribution of
atropine-sensitive and M2/M4 AChR-dependent GBMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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protein activity [36,44,45], the cholinergic agonist carba-
chol (CCh) stimulated [35S]GTPγ S binding to multiple
gray matter regions, including the striatum (Str), the tha-
lamic structures, with the most intense responses in the
superficial gray layer of the superior colliculus (SuG), as
well as various brainstem (bs) nuclei. In all visible
regions, CCh-stimulated G protein activity was robustly
amplified by GSNO. This was particularly evident in the
above-mentioned M2/M4 receptor-enriched anatomical
loci. It is noteworthy that the GSNO effects were fully
reversed in all regions in the presence of DTT or GSH (Fig-
ure 1, Supplementary Figure 1 [see additional file 1]). As
further illustrated in Figure 1, the P2Y receptor agonist 2-
methylthio-ADP (2MeSADP) activated G proteins both in
gray and white matter regions, producing a heterogeneous
activity pattern with characteristic "hot spot" appearance,
as described earlier [41,42]. Previous studies have estab-
lished that the 2MeSADP-stimulated G protein activity in
rat brain sections is mediated by a P2Y receptor subtype
that pharmacologically corresponds to P2Y12 [41,42]. In
contrast to the robust amplification of M2/M4 receptor-
dependent G protein activity, GSNO clearly inhibited
P2Y12 receptor signaling (Figure 1, Supplementary Figures
1 and 2 [see additional file 1]). This inhibition was evi-
dent throughout the effective agonist concentration range
(10-7 -10-4 M 2MeSADP), and responses to the endog-
enous agonist ADP (5 × 10-5 - 10-3 M) were similarly
blunted (Supplementary Figure 2 [see additional file 1]).
The GSNO-effect was fully reversible upon addition of
DTT or GSH (Figure 1, Supplementary Figure 1 [see addi-
tional file 1]). In the developing rat brain, LPA-stimulated
Gi protein activity is largely restricted to the myelinating
S-nitrosoglutathione (GSNO) reversibly modulates basal and receptor-dependent G protein activity in rat brain cryostat  sections Figure 1
S-nitrosoglutathione (GSNO) reversibly modulates basal and receptor-dependent G protein activity in rat 
brain cryostat sections. [35S]GTPγ S autoradiography of sagittal brain sections was conducted using a 3-step protocol with 
DPCPX (10-6 M) present throughout steps 2 and 3, as detailed in the Methods section. Where indicated, GSNO (0.5 mM) was 
present for 60 min during the GDP loading (step 2). When used, DTT (1 mM) or GSH (1 mM) were present during the 
[35S]GTPγ S labeling (step 3). The muscarinic agonist, carbachol (CCh, 10-4 M), the P2Y receptor agonist 2-methylthio-ADP 
(2MeSADP, 10-5 M) or lysophosphatidic acid (LPA, 5 × 10-5 M in 0.1% fatty acid free BSA) were present in step 3. In the control 
panel (left), the anatomical loci where receptor agonists typically activate G proteins are indicated. Note GSNO-dependent 
overall increase in basal G protein activity, as well as robust amplification of CCh-stimulated G protein activity in several gray 
matter regions visible at this sagittal plane, most notably the brain stem (bs) nuclei, the striatum (Str), and the superficial gray 
layer of the superior colliculus (SuG). Note also clear attenuation of 2MeSADP-stimulated responses in all brain regions, and 
blunting of LPA-stimulated responses, especially in the white matter areas, including the corpus callosum (cc), the fimbria of the 
hippocampus (fi) and the cerebellar white matter (Cbw). Scale bar = 2 mm. For quantitative data on selected brain regions, see 
Supplementary Figs. 1 and 2 in additional file 1.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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GSNO modulates GPCR signaling in a dose-dependent manner Figure 2
GSNO modulates GPCR signaling in a dose-dependent manner. [35S]GTPγ S autoradiography was conducted using a 
3-step protocol with DPCPX (10-6 M) present throughout steps 2 and 3, as detailed in the Methods section. GSNO was present 
at the indicated concentrations for 60 min during the GDP loading (step 2). Carbachol (CCh, 10-4 M), 2MeSADP (10-6 M) or 
LPA (5 × 10-5 M in 0.1% fatty acid free BSA) were present in step 3. Note dose-dependent amplification of CCh-stimulated G 
protein activity, most evident at this coronal plane in the cerebral cortex (Cx), the striatum (Str), and the thalamus (Thal). 
Note also dose-related attenuation of 2MeSADP- and LPA-stimulated responses, especially in the white matter regions, includ-
ing the corpus callosum (cc), the fimbria of the hippocampus (fi), and the striatal white matter (Sw). Scale bar = 2 mm. For 
quantitative data on selected brain regions, see Supplementary Figs. 1 and 2 in additional file 1.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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white matter tracts [36,41,43] (Figure 1), closely reflecting
the anatomical distribution of LPA1 receptor subtype [Ref.
36, and references therein]. Similar to the P2Y12
responses, LPA1 receptor responses were suppressed in
GSNO-treated sections throughout the white matter
tracts. Also this effect was fully reversed in the presence of
thiols (Figure 1, Supplementary Figure 1 [see additional
file 1]).
GSNO is present in significant amounts (~15 pmol/mg
protein) in the brain tissue and it is thought to act as a
physiological carrier of NO for S-nitrosylation reactions
[46,47]. As shown in Figure 2 and Supplementary Figure
1 [see additional file 1], GSNO modulated GPCR
responses in a dose-dependent manner, being effective at
the submillimolar concentration range. However, the
threshold and maximal concentrations needed for the
modulation of distinct receptors slightly varied. Potentia-
tion of M2/M4 receptor signaling was evident already
with 0.05 mM GSNO, but statistically significant
responses were obtained using 0.2 – 1 mM GSNO (Sup-
plementary Figure 1 [see additional file 1]). P2Y12 receptor
responses were inhibited with 0.2 mM GSNO and higher
concentrations (Figure 2, Supplementary Figure 1 [see
additional file 1]). LPA1 receptor signaling was only mar-
ginally affected with 0.05 mM GSNO, but was severely
blunted with 0.2 mM GSNO and higher concentrations
(Figure 2, Supplementary Figure 1 [see additional file 1]).
Collectively, these experiments demonstrate that GSNO, a
physiologically relevant RSNO, can modulate GPCR sign-
aling in discrete brain regions in a receptor-specific and
fully reversible manner.
Various RSNOs, including S-nitrosocysteine (CysNO)
(Figure 3, Supplementary Table 1 [see additional file 1]),
S-nitrosocysteamine, S-nitroso-L-cysteinylglycine
(CysNO-Gly), L-γ -glutamyl-S-nitrosocysteine (Glu-
CysNO), and S-nitroso-N-acetyl-D,L-penicillamine
(SNAP) – a compound with a sterically hindered SNO
group – mimicked the effects of GSNO on the three stud-
ied receptors (Figure 3, Supplementary Figure 2 [see addi-
tional file 1], and data not shown). When equimolar
concentrations (0.5 mM) of GSNO and SNAP were com-
pared, SNAP equally well suppressed P2Y12  receptor
responses, whereas GSNO more efficiently modulated
M2/M4 and LPA1 receptor responses (Supplementary Fig-
ure 3 [see additional file 1]). The modulatory effect of
CysNO on the three receptors was reversed by addition of
DTT or cysteine (Supplementary Figure 4 [see additional
file 1]). However, when "aged" CysNO was used (the
stock solution was left to stand for 2 days in ambient light,
oxygen and temperature), receptor-stimulated G protein
activity was almost completely abolished (Supplementary
Figure 5 [see additional file 1]).
Previous studies have suggested that RSNOs can act as
NO+, NO., and NO- donors under physiological condi-
tions [9]. The RSNO effects on GPCR responses were not
mimicked by the NO donor sodium nitroprusside (SNP),
when tested at similar (0.5 mM) concentrations (Figure 3,
Supplementary Table 1 [see additional file 1]). Further-
more, the NO+-releasing NO donor, nitrosodium
tetrafluoroborate (NOBF4, 0.5 mM) (data not shown),
hydrogen peroxide (1 mM H2O2 + 0.2 mM FeSO4) (data
not shown), or the cyclic GMP analog 8-bromo-cyclic
GMP (0.25 mM) (Figure 3, Supplementary Table 1 [see
additional file 1]) were largely ineffective. For selected
brain regions, quantitative autoradiography data on
CysNO, SNP and 8-bromo-cyclic GMP are presented in
the Supplementary Table 1 [see additional file 1].
The above results demonstrate that the effects of NO-
related species was shared by -and restricted to – different
classes of RSNO compounds, suggesting that S-nitrosyla-
tion rather than other types of NO reactions, or cGMP-
dependent mechanisms, were involved. According to the
S-nitrosylation scheme, treatment with exogenous RSNOs
should result in transnitrosylation of potential protein
thiols (R-SNO + Protein-SH ↔  R-SH + Protein-SNO). To
demonstrate the presence of SNO moieties in GSNO-
treated brain section, we used the indirect approach where
heterolytic cleavage of S-NO bond with HgCl2 generates
nitrite which can be measured by a colorimetric method.
To this end, brain sections were treated with GSNO (0.5
mM), and after thorough washes, the sections were incu-
bated further in the absence or presence of HgCl2 (10-4 M).
These experiments (shown in Supplementary Figure 6 [see
additional file 1]) revealed that HgCl2-catalyzed nitrite
formation was significantly higher in GSNO treated sec-
tions than that in control conditions (2.46 ± 0.13 vs. 0.61
± 0.14 nmol NO2
- per four coronal brain sections, mean ±
SE, n = 3, P < 0.001). Collectively these experiments sug-
gest that the RSNO-evoked and receptor-specific modula-
tion of GPCR signaling in brain sections most likely
involves S-nitrosylation mechanisms.
RSNOs modulate GPCR signaling in native tissues in a 
highly receptor-specific manner
Although [35S]GTPγ S autoradiography offers the advan-
tage of monitoring G protein activity simultaneously in
multiple brain regions with minimal disturbance of the
GPCR microenvironment, generating quantitative data
from the autoradiography images is relatively tedious. As
a complementary approach, we tested the effect of RSNOs
on agonist potency and efficacy for several additional Gi-
coupled receptors using classical membrane and lysate
[35S]GTPγ S binding assays. The results of these experi-
ments are summarized in Table 1. There was one major
difference from the situation with brain sections; in the rat
forebrain membrane preparations GSNO did notBMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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S-nitrosocysteine (CysNO) mimics the effects of GSNO in modulating GPCR signaling, whereas sodium nitroprusside (SNP)  and 8-bromo cyclic GMP (8Br-cGMP) do not Figure 3
S-nitrosocysteine (CysNO) mimics the effects of GSNO in modulating GPCR signaling, whereas sodium nitro-
prusside (SNP) and 8-bromo cyclic GMP (8Br-cGMP) do not. [35S]GTPγ S autoradiography was conducted using a 3-
step protocol with DPCPX (10-6 M) present throughout steps 2 and 3, as detailed in the Methods section. Where indicated, 
CysNO (1 mM), SNP (0.5 mM), or 8Br-cGMP (0.25 mM) were present for 60 min during the GDP loading (step 2). Carbachol 
(10-4 M), 2MeSADP (10-6 M), or LPA (5 × 10-5 M in 0.1% fatty acid free BSA) were present in step 3. Note amplification of CCh-
stimulated G protein activity by CySNO, most evident at this coronal plane in the cerebral cortex (Cx), the thalamus (Thal), 
including the superficial gray layer of the superior colliculus (SuG). Note also CysNO-dependent attenuation of 2MeSADP- and 
LPA-stimulated responses, most evident in the corpus callosum (cc) and the fimbria of the hippocampus (fi). Scale bar = 2 mm. 
For quantitative data on selected brain regions, see Supplementary Table 1 in additional file 1.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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significantly affect basal G protein activity (102 ± 2 % con-
trol, mean ± SE, n = 26, see also Figures 6 and 7). How-
ever, GSNO modulation of receptor-mediated responses
was found to be highly receptor-specific. In line with the
autoradiography data, M2/M4 receptor signaling was
markedly amplified (both the potency and the efficacy of
agonist increased) whereas LPA-evoked signaling efficacy
(but not agonist potency) was significantly decreased in
the rat forebrain membrane preparations. Moreover, the
efficacy of cannabinoid CB1 receptor signaling was signif-
icantly inhibited with no concomitant change in agonist
potency (Table 1). [35S]GTPγ S autoradiography studies
further indicated that CB1 receptor signaling was similarly
inhibited in various CB1 receptor-enriched brain regions,
including the cerebral cortex, the hippocampus and the
globus pallidus (Supplementary Figure 7 [see additional
file 1]). On the other hand, signaling via other widely dis-
tributed receptors, such as adenosine A1, µ-opioid (MOR)
and opiate-related receptor (ORL1), was only marginally
(A1 and ORL1), or not detectably (MOR), altered in bulk
membrane preparations (Table 1) or in brain cryostat sec-
tions (Figure 4). For the three receptors, quantitative auto-
radiography data on selected brain regions are presented
in Supplementary Table 2 [see additional file 1].
CHO cells express endogenous Gi-coupled LPA receptors
[48-50], and similarly to the situation in brain mem-
branes and cryostat sections, GSNO significantly inhib-
ited LPA signaling in CHO cell lysates without affecting
the agonist potency (Table 1). Platelets offer another read-
ily accessible model to study P2Y12-Gi (specifically Gα i2)
signaling in native cellular environments [42,51,52]. In
human platelet membranes, GSNO inhibited basal G pro-
tein activity by 22 ± 4 % (mean ± SE, n = 3). This effect was
statistically significant. Similar to the situation with brain
P2Y12 receptor signaling, GSNO inhibited P2Y12 receptor-
dependent G protein activity in human platelet mem-
branes, but had no effect on the agonist potency (Table 1).
To examine whether the receptor protein serves as a direct
target of this action, human P2Y12 receptor was stably
transfected into CHO cells. Several cell lines responding
to 2MeSADP in [35S]GTPγ S binding assays were
established (our unpublished observations). However,
neither GSNO nor CysNO affected the 2MeSADP dose-
response curves of any of the hP2Y12-expressing cell lines
(Figure 5 and data not shown). These data rule out the
P2Y12 receptor protein as a direct target of the RSNO
action.
The inhibitory effect of GSNO on basal and P2Y12 recep-
tor-dependent G protein activity was not due to a
nonspecific action on platelet membranes, since the sign-
aling of another Gi-linked platelet receptor, the α 2A-adren-
oceptor, was significantly amplified in GSNO-treated
membranes (Table 1). This effect was not restricted to
platelets, nor was it unique to the α 2A-subtype, as signal-
ing of the three human α 2-adrenoceptor subtypes (α 2A,
α 2B, and α 2C) was potentiated by GSNO in CHO cell lines
stably expressing these receptors (our unpublished
observations).
Table 1: Effects of GSNO treatment on agonist dose-response parameters in [35S]GTPγ S binding assays of various Gi-coupled 
receptors in their native cellular environment. Membranes or lysates were preincubated in control conditions or in the presence of 0.5 
mM GSNO for 30 min. Values are mean ± SE from three to four independent experiments performed in duplicate. Emax is expressed in 
percentage over basal with nonspecific binding subtracted.
Control GSNO
Receptor (agonist) log(EC50)E max (%) log(EC50)E max (%)
Rat forebrain membranes
M2/M4 mAChRs (CCh) -4.94 ± 0.05 176 ± 2 -5.55 ± 0.11** 207 ± 4**
LPA1 (LPA) -6.84 ± 0.26 140 ± 7 -6.53 ± 0.40 116 ± 3*
Cannabinoid CB1 (CP55940) -7.84 ± 0.07 223 ± 3 -7.69 ± 0.08 183 ± 2***
Adenosine A1 (2ClAdo) -6.90 ± 0.04 256 ± 3 -6.87 ± 0.12 234 ± 7*
µ-opiate (DAMGO) -6.85 ± 0.09 167 ± 3 -7.31 ± 0.19 164 ± 5
ORL1 (Nociceptin) -8.66 ± 0.12 173 ± 3 -8.78 ± 0.10 161 ± 2*
CHO cell lysates
LPA (LPA) -7.37 ± 0.11 202 ± 4 -7.05 ± 0.12 176 ± 4**
Human platelet membranes
P2Y12 (MeSADP) -8.19 ± 0.03 279 ± 2 -8.30 ± 0.08 195 ± 3***
α 2A-adrenoceptor (NA) -5.33 ± 0.08 161 ± 2 -5.49 ± 0.09 182 ± 3**
* Statistically different from control (P < 0.05)
** Statistically different from control (P < 0.01)
*** Statistically different from control (P < 0.001)BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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RSNOs amplify muscarinic responses by increasing the 
rate of GDP/GTP exchange and the number of high-
affinity GTP binding sites
The amplification of M2/M4 responses by RSNOs was
clearly evident in native brain tissue. Further experiments
were designed to address the mechanism of this action.
Results of these studies are presented in Figures 6 and 7. A
time-response study on basal and CCh-stimulated
[35S]GTPγ S binding responses in forebrain membranes
revealed that GSNO accelerated the rate of [35S]GTPγ S
binding in agonist-stimulated conditions (Figure 6). In
contrast, GSNO had no effect on basal guanine nucleotide
exchange. Given that GDP release is generally thought to
be the rate-limiting step in receptor-driven G protein
activation, these data indicate that the amplifying effect of
GSNO on M2/M4 receptor-stimulated G protein activity is
due to an accelerated rate of GDP/GTP exchange at the
receptor-activated G protein α  subunits. In line with this,
GSNO significantly increased the number of high-affinity
[35S]GTPγ S binding sites available for M2/M4 receptor
activation under agonist-stimulated conditions (Figure 7)
GSNO only marginally affect opiate related receptor (ORL1),  µ opioid receptor (MOR) and adenosine A1 (Ado A1) recep- tors signaling in brain sections Figure 4
GSNO only marginally affect opiate related receptor 
(ORL1), µ opioid receptor (MOR) and adenosine A1 
(Ado A1) receptors signaling in brain sections. 
[35S]GTPγ S autoradiography was conducted using a 3-step 
protocol with adenosine deaminase (ADA, 1 U/ml) present 
throughout steps 2 and 3, as detailed in the Methods section. 
Where indicated, GSNO (1 mM) was present for 60 min 
during the GDP loading (step 2). Protease inhibitor cocktail 
was included in step 2 for brain sections used for testing 
ORL1 and MOR responses. Receptor agonists nociceptin 
(ORL1), DAMGO (MOR), and 2-chloroadenosine (2ClAdo) 
(adenosine A1 receptor) were present at submaximal con-
centrations during step 3. Note wide distribution of nocicep-
tin-responsive brain regions, including the cerebral cortex 
(Cx). Note also robust response to DAMGO in the MOR-
enriched striatal patches (Sp), as well as the relatively GSNO-
resistant, and widely distributed adenosine A1 receptor-
dependent signal throughout the sagittal plane. Scale bar = 2 
mm. For quantitative data on selected brain regions, see Sup-
plementary Table 2 in additional file 1.
The P2Y12 receptor is not a direct target of RSNO action Figure 5
The P2Y12 receptor is not a direct target of RSNO 
action. Human P2Y12 receptor was stably expressed in 
CHO cells and agonist-stimulated G protein activity was 
determined in control conditions and in membranes pre-
treated for 30 min with 0.5 mM GSNO or CysNO, as 
detailed in the Methods section. There were no statistical dif-
ferences in the agonist potency [log (EC50): control -9.20 ± 
0.09; GSNO -9.14 ± 0.07; CysNO -9.27 ± 0.14) or efficacy 
[Emax (% basal): control 182 ± 3 %; GSNO 180 ± 2; CysNO 
179 ± 5%]. Values are mean ± SE from three independent 
experiments performed in duplicate.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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(Mean ± SE: CCh-control 1.49 ± 0.02 vs. CCh-GSNO 1.75
± 0.02 pmol/mg protein, P < 0.001, unpaired T-test). In
contrast, there were no statistical differences in the
potency of GTPγ S to displace [35S]GTPγ S in any of the
tested conditions (Figure 7) [log (EC50) ± SE: basal-con-
trol -8.10 ± 0.07; basal-GSNO -8.11 ± 0.12; CCh-control -
8.06 ± 0.06; CCh-GSNO -8.10 ± 0.04). These experiments
indicate that RSNOs amplify muscarinic receptor-stimu-
lated G protein activity in native brain tissue by accelerat-
ing the rate by which agonist-occupied receptors can
activate their cognate G proteins.
RSNO amplification of M4 receptor responses are 
preserved under heterologous expression but the 
amplification is lost with constitutive receptor activity
To investigate the signaling of the human M4 receptor
(hM4) under heterologous expression system, the recep-
tor was stably transfected into CHO cells. The effects of
GSNO on agonist-stimulated G protein activity were com-
pared in rat forebrain membranes and three cell lines
expressing the wild-type (WT) hM4 receptor with increas-
ing capability to activate G proteins. The results of these
experiments are shown in Figure 8, and the potency and
efficacy values are summarized in Table 2. In control
conditions, CCh stimulated [35S]GTPγ S binding in the
three WT-hM4 cell lines at a similar potency but varying
efficacy (Emax ranging from 134 to 586 %) (Figure 8, Table
2). GSNO treatment significantly increased the Emax in the
two WT-hM4 cell lines (E5 and C2) that showed
comparable maximal responses to the values obtained in
rat forebrain membranes (Figure 8, Table 2). In contrast,
the potentiating effect of GSNO was lost in the WT-hM4-
A1 cell line, where CCh robustly activated G proteins (Fig-
ure 8, Table 2). In contrast to the situation in brain mem-
branes and other hM4 cell lines of this study, WT-hM4-A1
cell line exhibited constitutive activity, i.e. significant G
protein activation was evident in the absence of added
agonist. In this cell line, the mAChR antagonist, atropine,
GSNO accelerates the rate of M2/M4 AChR-stimulated  [35S]GTPγ S binding to rat forebrain membranes but has no  effect on basal guanine nucleotide exchange rate Figure 6
GSNO accelerates the rate of M2/M4 AChR-stimu-
lated [35S]GTPγ S binding to rat forebrain mem-
branes but has no effect on basal guanine nucleotide 
exchange rate. Membranes were preincubated for 30 min 
in control conditions or in the presence of 0.5 mM GSNO, 
and time-response for basal and CCh-stimulated (10-4 M] 
[35S]GTPγ S binding was determined, as detailed in the Meth-
ods section. Values represent specific binding (mean ± SD of 
duplicate determinations) from one representative experi-
ment that was replicated three times with similar outcome.
GSNO increases the number of M2/M4 AChR interacting  high-affinity [35S]GTPγ S binding sites in rat forebrain  membranes Figure 7
GSNO increases the number of M2/M4 AChR inter-
acting high-affinity [35S]GTPγ S binding sites in rat 
forebrain membranes. Membranes were preincubated for 
30 min in control conditions or in the presence of 0.5 mM 
GSNO, and incubated thereafter for 90 min with 0.15 nM 
[35S]GTPγ S, 10-5 M GDP and indicated concentrations of 
unlabeled GTPγ S in the presence and absence of CCh (10-4 
M), as detailed in the Methods section. Statistical comparison 
of one- versus two-site competition curves (nonlinear 
regression) indicated that the one-site model best described 
GTPγ S displacement in agonist-stimulated conditions. Note 
that GSNO significantly increased the number of high-affinity 
[35S]GTPγ S binding sites in CCh-treated membranes (CCh-
control 1.49 ± 0.02; CCh-GSNO 1.75 ± 0.02 pmol/mg pro-
tein, P < 0.001, unpaired T-test). There were no statistical 
differences in the potency for GTPγ S in displacing radioligand 
in any condition [log (EC50): basal-control -8.10 ± 0.07; basal-
GSNO -8.11 ± 0.12; CCh-control -8.06 ± 0.06; CCh-GSNO 
-8.10 ± 0.04). Values represent specific binding (mean ± SE) 
from three independent experiments performed in duplicate.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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significantly inhibited basal G protein activity by 13 ± 3 %
(mean ± SE, n = 3, P < 0.05) (Figure 8, bottom panel mid-
dle). The effect was dose-dependent [log(IC50) -8.48 ±
0.23 (mean ± SE, n = 3)], indicating increased constitutive
activation of WT-hM4 receptor in this cell line. Collec-
tively these experiments indicate that the potentiating
effect of GSNO on hM4 receptor responses was preserved
under heterologous expression but that the effect was
diminished with constitutive receptor activity.
The final experiments were intended to clarify whether
cysteine 133 (C133), located adjacent to the G protein-
interacting DRY-motif in the intracellular end of trans-
membrane helix 3 of the Gi-coupled muscarinic receptors
(M2/M4), could serve as the molecular target of RSNO
action. To this end, C133 was mutated into serine to
reveal if the C133S mutation would abolish the effect of
GSNO on the efficacy of CCh. However, GSNO treatment
significantly increased Emax also in the mutant C133S-
hM4 cell line (Figure 8, bottom panel right, Table 2), indi-
cating that cysteine C133 of the hM4 receptor is not the
specific target of RSNOs. The mutation did not affect the
potency of CCh to activate G proteins via the hM4 recep-
tor (Table 2).
Discussion
[35S]GTPγ S autoradiography of brain cryostat sections
revealed a highly receptor-specific modulation of GPCR
signaling by RSNOs in several receptor-enriched
anatomical structures. This modulation was fully reversi-
ble upon addition of excess thiols. We have provided evi-
dence indicating that S-nitrosylation, rather than other
types of NO reactions or the NO – guanylyl cyclase –
cGMP signaling pathway, was responsible for the
observed effects. The RSNOs effects were receptor-specific,
as signaling of some receptors was markedly potentiated
(M2/M4 AChRs and α 2-adrenoceptors), whereas that of
others was clearly inhibited (P2Y12, LPA and cannabinoid
CB1 receptors), while signaling of other receptors was only
marginally affected (adenosine A1, MOR, and ORL1
receptors) by comparable treatments. We further demon-
strated that RSNOs can amplify M2/M4 receptor
responses by increasing the rate of GDP/GTP exchange as
well as the number of high-affinity G protein α  subunits
capable of interacting with the agonist-activated receptors.
The potentiating effect of RSNOs on hM4 receptor
responses was preserved when this was studied in a heter-
ologous expression system but was diminished in consti-
tutively active hM4 receptors. We also demonstrated that
the GPCR itself or its native signaling partners serve as
potential targets of this modulation, as it was attenuated,
or even lost, when receptor signaling was studied under
heterologous expression. Our study suggests that GPCR
signaling is subject to a highly receptor-specific modula-
tion by NO-derived RSNOs.
The GPCRs and their proximal signaling partners as likely 
targets of RSNO action
Since [35S]GTPγ S binding assays monitor G protein activa-
tion, one of the earliest measurable steps in GPCR signal
transduction, it is obvious that the molecular targets of
RSNO action are the receptors, their cognate G proteins
and/or additional signaling partners, whose thiol modifi-
cation can directly regulate guanine nucleotide binding
and hence G protein activation.
It is interesting that RSNO treatment of brain sections
consistently resulted in thiol-sensitive increases in basal
Gi protein activity throughout the gray matter regions.
However, no such effect was present in brain membrane
[35S]GTPγ S binding assays, nor was it detected in CHO
cell membranes but in platelet membranes, RSNOs inhib-
ited basal G protein activity by ~20%. As receptor input
should be minimal in basal conditions, the differential
Table 2: Effects of GSNO treatment on agonist (CCh) dose-response parameters in [35S]GTPγ S binding assays of hM4 cell line 
membranes. Membranes were preincubated in control conditions or in the presence of 0.5 mM GSNO for 30 min. Values are mean ± 
SE from three to four independent experiments performed in duplicate. Emax is expressed in percentage over basal with nonspecific 
binding subtracted.
Control GSNO
CHO cell line log(EC50)E max (%) log(EC50)E max (%)
hM4-WT-A1 -4.87 ± 0.14 586 ± 31 -4.94 ± 0.09 674 ± 23
hM4-WT-E5 -4.87 ± 0.05 213 ± 3 -4.98 ± 0.13 276 ± 10**
hM4-WT-C2 -5.21 ± 0.20 134 ± 3 -5.27 ± 0.20 154 ± 8*
hM4-C133S-H2 -5.13 ± 0.10 198 ± 4 -5.12 ± 0.11 235 ± 6**
* Statistically different from control (P < 0.05)
** Statistically different from control (P < 0.01)BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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behavior of RSNOs in cryostat sections and various mem-
brane preparations likely reflects direct action on the Gi
proteins and/or their proximal regulatory partners. It has
been known for some time that G proteins can serve as
direct targets of ROS, including NO [21-24,28,29]. Exoge-
nous NO donors stimulate the monomeric G protein
p21ras  via S-nitrosylation to a single cysteine residue
[22,53]. Furthermore, Gα i and Gα o serve as direct protein
targets of ROS, and they can be activated in the absence of
input from the GPCRs [29,33]. Specifically, ROS were
shown to modify two cysteine residues of Gα i/o and this
modification accelerated GDP release from Gα  with a
concomitant increase in the formation of the GTP-bound
form of Gα  without receptor activation [29,33]. Further-
more, GSNO was reported to stimulate basal G protein
activity in bovine aortic endothelial cells and human
peripheral blood mononuclear cells [22,26]. The RSNO-
elicited increase in basal G protein activity in brain sec-
tions is consistent with these findings. However, it is not
clear why no such stimulation was detected in bulk
membrane preparations. One explanation could be the
differential accessibility of target thiol(s) in cryostat sec-
tions as compared to membrane preparations. It is reason-
able to assume that thiol accessibility in the former
situation is close to natural. It is also possible that some
crucial regulatory component of the signaling machinery
is lost in bulk membrane preparations. Since several high-
speed centrifugation steps were employed to obtain the
GSNO-evoked potentiation of muscarinic signaling is preserved under heterologus expression but the effect diminishes with  increasing constitutive activity Figure 8
GSNO-evoked potentiation of muscarinic signaling is preserved under heterologus expression but the effect 
diminishes with increasing constitutive activity. The human M4 (hM4) receptor was stably transfected into CHO cells 
and wild type (WT) or mutant (C133S) cell lines with differential G protein activation capacity were compared with that in rat 
forebrain membranes. CCh-stimulated G protein activity was determined in control conditions and in membranes pretreated 
for 30 min with 0.5 mM GSNO, as detailed in the Methods section. Note that cell lines WT-C2, WT-E5 and C133S-H2 have 
maximal responses comparable to that in native brain tissue. Note also robust G protein activation in WT-A1 cell line, as well 
as its constitutive activity, as evidenced by the ability of the inverse agonist atropine to inhibit basal G protein activity in this cell 
line. Potency and efficacy values are summarized in Tables 1 (rat brain) and 2 (hM4 clones). Values are mean ± SE from at least 
three independent experiments performed in duplicate.BMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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relatively pure membrane preparation used in our study,
this possibility should not be underestimated. This could
also explain why RSNOs had no effect on basal G protein
activity in CHO cell membranes, although several mem-
bers of the Gi family, including Gα i1/2, Gα i3, and Gα o, are
endogenously present in these cells [54].
In platelet membranes, RSNOs inhibited both basal and
P2Y12 receptor-dependent G protein activity, but clearly
potentiated  α 2A-adrenoceptor responses. Platelet P2Y12
receptors couple to Gα i2 [51,52], whereas α 2A-adrenocep-
tors can communicate via Gα z, at least in the mouse [55].
Collectively these data suggest that RSNOs inhibit both
basal and receptor-stimulated Gα i2 activity in the plate-
lets. It is not yet known whether brain P2Y12 receptors
couple to this particular G protein subtype. Further, it is
unclear whether LPA receptors in brain and CHO cells
communicate via Gα i2. It is interesting that RSNOs inhib-
ited the signaling of all three receptors in native tissues. In
addition, we found that brain cannabinoid CB1 receptor
signaling was inhibited by RSNOs. A previous study
reported that pulmonary vasoconstriction by serotonin
was also inhibited by GSNO [34].
Although the basic module of GPCR signaling is tradition-
ally considered to be the receptor, its cognate G protein,
and the effector, recent studies have identified a wide
range of proteins that can directly interact with the recep-
tor and/or G proteins. These can modulate signaling effi-
ciency, cellular localization, or the regulation of the
GPCRs or G proteins [6]. One such recently-identified
protein is the brain-enriched, Ras-related monomeric G
protein Dexras1 (human counterpart is termed activator
of G protein signaling 1, AGS1). Dexras1/AGS1 is physio-
logically activated upon NMDA receptor-stimulated NO
synthesis and S-nitrosylation on cysteine C11 [56,57].
Dexras1/AGS-1 also interacts with Gα i/Gα o, and can acti-
vate GPCR signaling systems independently of receptor
input [6,58]. Interestingly, Dexras1/AGS-1 was shown to
proximally antagonize the signaling of M2 AChRs and
formyl peptide receptors, possibly by altering the pool of
G proteins available for receptor coupling and/or disrup-
tion of a preformed signaling complex [59,60]. It is cur-
rently unknown whether RSNOs and/or S-nitrosylation
could alter the ability of Dexras1/AGS-1 to modify G pro-
tein function and/or input from the GPCRs. In light of the
present findings, this should be an attractive hypothesis
for future studies.
Most Gα  proteins are palmitoylated at a cysteine near the
amino terminus and this modification is required for G
protein targeting to lipid rafts [61] and/or normal signal-
ing [62]. Addition and removal of the palmitoyl group
appear to be dynamic receptor-mediated processes that
may contribute to recycling of Gα  between the membrane
and cytosolic compartments [63]. Since our experiments
used only nonliving tissue, it is unlikely that the RSNO
actions would achieve such extensive lipid modifications,
although such alterations reportedly occur after exposure
of living cells to NO [64].
Functional implications
Specialized plasma membrane microdomains act as
unique platforms with specific enrichment of GPCRs,
their signaling partners, and the enzymatic machinery for
NO biosynthesis [35,37-40]. Such close proximity of the
GPCR signaling complex and NO source is particularly
relevant for many of the receptors whose signaling was
shown here to be reversibly modulated by RSNOs.
In the heart, endothelial NOS (eNOS) is localized n cave-
olin-enriched myocyte membrane fractions and it has
been shown that lipid draft-disrupting agents severely
compromise NO-dependent inhibition of adenylyl
cyclase types 5 and 6 [35]. M2-mediated parasympathetic
cardiac signaling also critically involves eNOS activation
and NO production [65]. On the other hand, caveolar
sequestration of M2 receptors and NO signaling was
shown to be finely tuned in the myocytes [66], suggesting
a dynamic interplay between the M2 receptor and NO. In
hM4 expressing CHO cells, SNP induced agonist-inde-
pendent internalization of the receptor via atropine- and
thiol-sensitive mechanisms [67]. Furthermore, ROS
including NO, potentiate cardiac M2 receptor signaling
via poorly defined mechanisms [32,68]. Consistent with
these findings, our study revealed robust amplification of
M2/M4 receptor signaling by RSNOs both in the brain
and in CHO cells expressing the hM4 receptor. In CHO
cells, however, the RSNO effect clearly diminished with
increasing constitutive receptor activity, suggesting that
RSNO action and constitutive receptor activity likely share
common mechanisms, including accelerated GDP/GTP
exchange in cognate Gα  subunits. As far as we are aware,
this is the first study to show robust, and highly region-
specific amplification of M2/M4 receptor signaling in dis-
crete anatomical loci of the central nervous system. The
functional consequences of these findings remain to be
established.
The P2Y12 receptor plays a central role in platelet activa-
tion and aggregation [69]. Previous studies have indicated
that endothelial and platelet-derived NO, as well as exog-
enous RSNOs, are potent inhibitors of platelet aggrega-
tion [70-73]. Both cGMP-dependent and -independent
mechanisms and several potential molecular targets have
been implicated in these effects [72,74]. A previous report
provided evidence for cGMP-mediated signaling in the
inhibition of platelet Gi signaling [74]. The present study
adds further dimensions to this scheme by demonstrating
that RSNOs can inhibit platelet (and brain) P2Y12 receptorBMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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function via cGMP-independent mechanisms, likely
involving S-nitrosylation. However, since the effect was
lost in CHO cells stably expressing the hP2Y12 receptor,
the native signaling partners, rather than the P2Y12 recep-
tor, serve as obvious targets of this action.
One of the novel findings in this study was that RSNOs
strongly inhibited Gi-mediated LPA receptor signaling in
the brain and in CHO cells. The relevance of this finding
with respect to brain LPA1 receptor signaling remains to be
established. In vivo, peripheral LPA receptor signaling is
closely associated with NO. In bovine aortic endothelial
cells, LPA stimulates endothelial NOS via Gi-coupled LPA
receptors [75]. LPA is released from activated platelets and
this stimulates other platelets to activate aggregation proc-
esses [76,77]. Inhibition of LPA signaling via endogenous
RSNOs could be one important mechanism by which
endothelium-derived NO can suppress LPA-mediated
athero- and thrombogenic signaling.
Conclusion
In conclusion, this study revealed that G protein activa-
tion, an early step of GPCR signal transduction, is subject
to a reversible and highly receptor-specific modulation by
exogenous RSNOs at physiologically relevant
concentrations. Since NOS synthases (and thus NO pro-
duction) have been shown to reside in close proximity
with the GPCR signaling machinery, especially for many
of the receptors whose signaling is subject to modulation
by exogenous RSNOs, these findings suggest that GPCR
signaling in vivo is likely to be finely tuned by NO-derived
RSNO species. Future studies should aim at pinpointing
the precise molecular targets of these actions, and at
understanding the specific modifications (S-nitrosylation
and/or S-thiolation) involved, as well as revealing the
physiological and/or pathophysiological relevance in
vivo.
Methods
Materials
All drugs and chemicals were from Sigma (St. Louis, MO)
or Merck (Darmstadt, Germany), unless otherwise stated.
Cell culture media, sera, and antibiotics were from Euro-
clone (Pero, Italy). Protein concentrations were deter-
mined with Bio-Rad protein assay (Bio-Rad, Hercules, CA,
USA). Adenosine deaminase (ADA) was purchased from
Roche (Mannheim, Germany) and guanosine-5'-O-(3-
[35S]-thio)-triphosphate ([35S]GTPγ S; initial specific activ-
ity 1250 Ci/mmol) from NEN (Boston, MA). CP55940,
DAMGO, nociceptin, and SNAP were purchased from
Tocris Cookson Ltd. (Bristol, UK).
DNA constructs
Human M4 muscarinic receptor (hM4, gift from Dr.
Johnny Näsman, University of Kuopio) was subcloned
from pBluescript into pcDNA3 mammalian expression
vector and a triple hemagglutinin (HA) epitope tag was
subcloned after the initiating Met codon of the hM4 gene.
This construct was used to create a C133S mutant hM4
receptor with QuickChange Site Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). Human P2Y12  purinergic
receptor (hP2Y12) was amplified from QuickClone
human brain cDNA (Stratagene) using RT-PCR with gene-
specific primers. The PCR product was ligated into
pcDNA3 and a N-terminal hemagglutinin (HA) epitope
tag was inserted in a PCR reaction with 5' primer contain-
ing the HA tag DNA sequence. All receptor constructs were
confirmed by restriction analyses and DNA sequencing
prior to transfections.
Cell culture and transfection
Recombinant plasmids were introduced into Chinese
hamster ovary (CHO) cells with Lipofectamine 2000
transfection reagent (Gibco, Paisley, UK). Transfected
cells were placed under G-418 selection (600 µg/ml) and
several cell lines originating from single G-418 resistant
cells were isolated. The G-418 resistant cell lines were cul-
tured as monolayers with 100 µg/ml G-418 in Ham's F-12
nutrient mixture, containing 10% fetal calf serum, 100 U/
ml penicillin and 100 µg/ml streptomycin at 37°C in a
humidified atmosphere of 5% CO2 / 95% air. Stable cell
lines were analyzed for HA tag (and thus receptor) expres-
sion using receptor ELISA with mouse anti-HA primary
antibody [78]. The cell lines that showed high receptor
expression levels in receptor ELISA were maintained for
subsequent experiments. From these, several hM4 and
hP2Y12  cell lines were established that responded to
carbachol (CCh) or 2-methylthio-ADP (2MeSADP),
respectively. Nontransfected CHO cells did not respond to
CCh (data not shown). CHO cells endogenously express
Gq-coupled P2Y receptors (P2Y1 and P2Y2). However,
CHO cells that had not been transfected with the hP2Y12
receptor construct did not respond to 2MeSADP,
indicating that activation of Gq was not detected using
[35S]GTPγ S binding assays (data not shown).
Preparation of cryostat sections, membranes, and cell 
lysates
Naïve, four-week-old male Wistar rats were used for the
preparation of brain cryostat sections essentially as
described earlier [41,79]. All animal protocols were
approved by the local ethics committee. Platelet mem-
branes were prepared from expired human platelets (Red
Cross, Helsinki, Finland) as previously described [42],
except that protease inhibitor cocktail was omitted. CHO
cells were harvested by scraping in PBS containing 5 mM
EDTA. Membrane fractions (P2) from rat brains and hM4
cell lines were isolated with differential centrifugation
using previously published protocols [80,81]. For mem-
brane preparation from hP2Y12-expressing cell lines, theBMC Cell Biology 2005, 6:21 http://www.biomedcentral.com/1471-2121/6/21
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centrifugation method used for platelet membrane prepa-
ration [42] was used, with the modification of omitting
the protease inhibitor cocktail. For the preparation of
whole-cell lysates, the cells were harvested by trypsiniza-
tion in normal growth medium. Cell density was counted
in a hemocytometer and the cells were pelleted by centrif-
ugation for 10 min at 250 × g at room temperature. The
cell pellets were washed with PBS and centrifuged twice as
above, after which the dry pellets were snap-frozen on dry
ice. The frozen pellets were thawed for 1 min in a water
bath at room temperature, after which snap-freezing was
repeated. The final membrane and lysate preparations (1–
5 mg protein/ml) were stored as single-use aliquots in -
75°C.
Preparation of S-nitrosothiols
S-nitroso-N-acetyl-D,L-penicillamine (SNAP) was pur-
chased from Tocris Cookson Ltd. (Bristol, UK). All other
RSNOs were synthesized from the respective thiols using
acidified NaNO2. For example, S-nitrosoglutathione
(GSNO) was prepared by mixing 100 µl sodium nitrite
(100 mM) with 100 µl HCl (150 mM) and adding 100 µl
reduced glutathione (100 mM). Reactions were allowed
to proceed for 10 min at room temperature, protected
from light. Reaction mixtures were neutralized with 150
µl NaOH (100 mM) and used immediately in the experi-
ments. Millipore-quality water was used throughout and
the assay buffer routinely contained 1 mM EDTA. The
concentrations of RSNOs were determined by UV spec-
troscopy using previously published [70] values for the
molar absorption coefficients (ε ) and absorption maxima
(λ max).
[35S]GTPγ S autoradiography
The assay was conducted under optimized conditions,
where basal noise due to tonic adenosine A1 receptor
activity has been eliminated [79]. Experiments were con-
ducted in light-protected chambers and in the absence of
dithiotreitol (DTT), unless indicated otherwise. Briefly,
the assay consisted of preincubation for 20 min at 20°C
in buffer A (50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 100
mM NaCl, 5 mM MgCl2), followed by GDP loading and
RSNO treatment for 1 h at 20°C in buffer A, containing
additionally 2 mM GDP and 8-cyclopentyl-1,3-dipropylx-
anthine (DPCPX, 10-6 M) or adenosine deaminase (ADA,
1 U/ml) to eliminate tonic adenosine A1 receptor activity.
When peptide agonists were used, protease inhibitor cock-
tail (Sigma P-2714) was included in step 2 at the concen-
trations recommended by the manufacturer. For
[35S]GTPγ S binding, sections were incubated for 90 min at
20°C in buffer A, containing additionally 80 pM
[35S]GTPγ S, 2 mM GDP, DPCPX (10-6 M) or ADA (1 U/
ml), and the receptor agonists and/or reduced thiols
(DTT, GSH or cysteine), as detailed in the results section.
Nonspecific binding (Nsb) was determined in the pres-
ence of 10 µM GTPγ S. The sections were washed twice at
0°C for 5 min in washing buffer (50 mM Tris-HCl, 5 mM
MgCl2, pH 7.4), rinsed in ice-cold deionized water for 30
s, air dried and apposed to Biomax™ MR film (Kodak) for
6–11 days. Autoradiography images were digitized and
processed for figures, as previously described [41].
[35S]GTPγ S membrane binding assays
The incubations were carried with slight modifications to
previously published protocols [80,81]. Membranes or
lysates were preincubated for 30 min at room temperature
in 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 100 mM NaCl,
5 mM MgCl2, 10 µM GDP and 0.5 U/ml ADA, under con-
stant shaking and protected from light. RSNOs (usually
GSNO or CysNO) were included in the preincubation at
final concentrations of 0.5 mM. The assay was performed
in duplicate in a final assay volume of 400 µl. The reaction
was initiated by adding 40 µl of membrane or lysate prep-
aration (5 µg protein or 50,000 cells / tube) to incubation
tubes containing drug dilutions and binding cocktail. The
final concentrations of the components in binding reac-
tion were 50 mM Tris-HCl (pH 7.4), 1 mM EDTA, 100
mM NaCl, 5 mM MgCl2, 0.5% BSA, 10 µM GDP, 0.5 U/ml
ADA and 150 pM [35S]GTPγ S. Nsb was defined using 10
µM GTPγ S. Reaction tubes were incubated for 90 min at
25°C under constant shaking. The reaction was quickly
terminated by the addition of 4 ml ice-cold wash buffer
(50 mM Tris-HCl (pH 7.4), 5 mM MgCl2) followed by
rapid filtration through Whatman GF/B glass fiber filters
(Whatman, Maidstone, UK) and two additional 4 ml
washes with the buffer. In the time-response study (Figure
6), initial reaction volume was 2 ml and aliquots (400 µl)
from duplicate samples were draw at different time points
(15, 30, 60 and 90 min), and the reaction was terminated
as described above. Radioactivity in filters was counted
with Wallac Rackbeta liquid scintillation counter (Wallac,
Turku, Finland). It should be noted that RSNO treatment
caused a small, yet consistent increase in Nsb (25 ± 4 %,
mean ± SEM, n = 13). However, as Nsb represented <0.3
% of total radioactivity, this effect was considered negligi-
ble and did not contribute to the results and conclusions
thereof.
Data analysis
[35S]GTPγ S-membrane binding data were analyzed with
GraphPad Prism software (GraphPad, San Diego, CA)
using non-linear fitting for sigmoid dose-response curves.
Statistical analyses were made with one-way analysis of
variance (ANOVA) followed by Tukey's multiple
comparison test. When comparison was made between
only two groups, unpaired T-test was used.
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